After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Lyra Therapeutics Inc. (LYRA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.04, or 1.15%, to $3.53. The Lyra Therapeutics Inc. has recorded 5 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis.
LYRA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $3.49 and fluctuated between $3.6754 as its day high and $3.3600 as its day low. The current market capitalization of Lyra Therapeutics Inc. is $172.41M. A total of 52304.0 shares were traded on the day, compared to an average of 173.12K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, LYRA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 9 BUYs and 0 SELLs from insiders. Insiders purchased 7,288,331 shares during that period but sold 0.
In the most recent transaction, PERCEPTIVE ADVISORS LLC bought 3,610,832 shares of LYRA for 2.49 per share on May 31. After the transaction, the Director now owns 11,469,117 company shares. In a previous transaction on May 31, NBVM GP, LLC bought 1,805,416 shares at 2.43 per share. LYRA shares that 10% Owner owns now total 2,521,745.
Among the insiders who bought shares, ANDERSON EDWARD T acquired of 1,805,416 shares on May 31 at a per-share price of $2.43. This resulted in the Director holding 2,521,745 shares of LYRA after the transaction.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for LYRA in the last 3 months, the mean price target is $12.00 with high estimates of $15.00 and low estimates of $8.00. In terms of 52-week highs and lows, LYRA has a high of $6.48 and a low of $1.86.
As of this writing, LYRA has an earnings estimate of -$0.33 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.29 per share and a lower estimate of -$0.37. The company reported an EPS of -$0.44 in the last quarter, which was -22.20% lower than expectations of -$0.36.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. LYRA’s latest balance sheet shows that the firm has $45.75M in Cash & Short Term Investments as of fiscal 2021. There were $1.45M in debt and $18.25M in liabilities at the time. Its Book Value Per Share was $2.26, while its Total Shareholder’s Equity was $34.32M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for LYRA is Buy with a score of 5.00.